Setmelanotide

Metabolic / Rare Disease

Also known as: Imcivree, RM-493

Melanocortin Receptor AgonistsResearch phase: FDA-approved, post-marketingRegulatory: FDA-approved (2020) for obesity due to POMC, PCSK1, or LEPR deficiency. Expanded 2022 to include POMC/PCSK1 heterozygous.

Mechanism

An FDA-approved injection for rare genetic obesity caused by specific gene mutations (POMC, PCSK1, LEPR deficiency). It works by activating the MC4R receptor in the brain that controls hunger and metabolism — the same receptor affected by PT-141 and MT-2, but this one is specifically designed for appetite regulation. Not for general weight loss.

Technical detail

Selective MC4R agonist (8-amino acid cyclic peptide). Restores MC4R signaling downstream of POMC, PCSK1, or LEPR gene defects. Mechanism: activates MC4R on paraventricular hypothalamic neurons, reducing hunger and increasing energy expenditure via sympathetic nervous system activation. Phase 3 trials showed 25.6% mean body weight reduction in POMC deficiency. Does not affect MC1R (minimal tanning). Side effects: skin hyperpigmentation (MC1R partial agonism), injection site reactions, erections.

Effects

## Setmelanotide (Imcivree) — System-by-System Effects ### Metabolic/Appetite System (Primary) - **MC4R agonism**: Setmelanotide is a selective melanocortin-4 receptor (MC4R) agonist. MC4R is the key receptor in the hypothalamic melanocortin pathway that controls satiety and energy expenditure. [Tier 1] - **Appetite reduction**: Restores satiety signaling in patients with genetic defects upstream of MC4R. Patients experience normalized hunger for the first time in their lives. [Tier 1 — pivotal trial data] - **Weight loss**: In pivotal trials, patients with POMC, PCSK1, or LEPR deficiency obesity lost 25-51% of body weight (mean ~25% BMI reduction). These are extraordinary results in a population that was previously treatment-resistant. [Tier 1] - **Energy expenditure**: MC4R agonism may also increase energy expenditure, contributing to weight loss beyond appetite effects. [Tier 2] ### Endocrine System - **Melanocortin pathway**: Setmelanotide activates MC4R, bypassing upstream defects in POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase), or LEPR (leptin receptor) pathways. This is a precision medicine approach — treating the specific molecular defect. [Tier 1] - **Leptin-melanocortin axis**: In normal physiology, leptin → POMC neurons → α-MSH → MC4R → satiety. Genetic defects at any point break this cascade. Setmelanotide restores signaling at the MC4R level. [Tier 1] - **Adrenal function**: MC4R is related to other melanocortin receptors (MC1R-MC5R). Selectivity for MC4R minimizes effects on adrenal function (MC2R) and pigmentation (MC1R), though some cross-reactivity occurs. [Tier 1] ### Dermatological - **Skin hyperpigmentation**: The most common side effect. Setmelanotide has some activity at MC1R, which regulates melanin production. Patients develop diffuse skin darkening. This is generally mild and cosmetically manageable but notable. [Tier 1 — clinical trial data] ### Sexual Function - **Penile erection**: MC4R agonism can cause spontaneous erections. This was a side effect noted with earlier melanocortin agonists (PT-141/bremelanotide was developed from this observation). Occurs in some male patients. [Tier 1]

Practitioner Guide

## Setmelanotide (Imcivree) — Practitioner Guide ### Clinical Profile Setmelanotide is an FDA-approved MC4R agonist for severe obesity due to specific genetic defects: POMC deficiency, PCSK1 deficiency, or LEPR deficiency. It is a landmark precision medicine therapy — the first approved drug targeting a specific genetic cause of obesity. ### Approved Indications (FDA, 2020) - Chronic weight management in patients aged ≥6 years with obesity due to: - POMC deficiency (homozygous or compound heterozygous loss-of-function variants) - PCSK1 deficiency - LEPR deficiency (added 2022) - Confirmed by genetic testing showing variants considered pathogenic, likely pathogenic, or of uncertain significance ### Dosing - **Initiation**: 2mg SC daily for 2 weeks - **Titration**: Increase to 3mg SC daily if tolerated - **Assessment**: If ≥5% weight loss is not achieved in 12-16 weeks at 3mg, consider discontinuation (genetic re-evaluation may be warranted) - **Administration**: Once-daily subcutaneous injection, rotating injection sites ### Genetic Testing Requirement - **Mandatory**: Setmelanotide requires confirmation of qualifying genetic mutations before prescribing - **Panel testing**: Obesity gene panels including POMC, PCSK1, LEPR, and related genes are commercially available - **Who to test**: Patients with severe, early-onset obesity (typically before age 5), hyperphagia out of proportion to social/behavioral factors, family history suggestive of monogenic obesity - **Prevalence**: These genetic forms are rare (estimated <1:1,000 of all obesity). However, they are likely underdiagnosed. ### Common Side Effects - **Skin hyperpigmentation** (75%+): Diffuse darkening of skin. Generally mild-moderate. Related to MC1R activity. - **Injection site reactions** (45%): Pain, erythema, pruritis at injection site. - **Spontaneous penile erection** (in males): MC4R-mediated. Usually mild and transient. - **Nausea/diarrhea**: GI symptoms in some patients. - **Depression/suicidal ideation**: Black box warning. Monitor mood, especially in adolescents. May relate to MC4R's role in mood regulation. ### Important Clinical Considerations - **This is NOT for common obesity**: Setmelanotide does not work for polygenic/lifestyle obesity. It specifically treats upstream melanocortin pathway defects. - **Think of it when you see**: Severe obesity starting in infancy/early childhood, insatiable hunger (true hyperphagia, not emotional eating), red hair or pale skin (POMC deficiency can cause this), adrenal insufficiency (POMC deficiency) - **Life-changing for the right patient**: Patients with these genetic forms of obesity often have extreme hyperphagia — literally uncontrollable hunger since birth. Setmelanotide can normalize their hunger. Families describe it as miraculous. - **Specialty prescribing**: Should be managed by endocrinologists or obesity medicine specialists familiar with genetic obesity. REMS-like monitoring is appropriate. ### Comparison with Other MC4R-Related Agents - **PT-141 (Bremelanotide)**: Non-selective melanocortin agonist approved for HSDD (sexual dysfunction). Different indication, less MC4R selectivity. - **Melanotan II**: Research peptide, non-selective melanocortin agonist. Used off-label for tanning and sexual function. NOT interchangeable with setmelanotide. Safety profile is worse. - **Setmelanotide advantage**: Highest selectivity for MC4R with least MC1R/MC3R/MC5R cross-reactivity among available melanocortin agonists.

Dosing Protocols

genetic_obesitybasic tier
Dose
2000mcg
Frequency
Once daily
Timing
Morning; titrate from 1mg for 2 weeks, then increase to 2mg; may increase to 3mg if insufficient response after 2 weeks at 2mg
Route
subcutaneous
Cycle
4-52 weeks

FDA-approved (Imcivree) for POMC, PCSK1, or LEPR deficiency obesity. Setmelanotide is a selective MC4R agonist that restores melanocortin signaling downstream of the genetic defect in the leptin-melanocortin pathway. NOT indicated for general obesity or polygenic obesity. Titrate per FDA label: 1mg daily x2 weeks, then 2mg daily, then 3mg daily if needed. Maximum 3mg/day. Pre-filled multi-dose vial provided.

genetic_obesityintermediate tier
Dose
3000mcg
Frequency
Once daily
Timing
Morning; maintenance dose after titration from 1mg to 2mg to 3mg per FDA label
Route
subcutaneous
Cycle
4-52 weeks

Maximum FDA-labeled dose for patients who did not achieve adequate response at 2mg/day after at least 2 weeks. Discontinue if no meaningful weight loss after 12 weeks at 3mg/day. Monitor for skin hyperpigmentation (MC1R cross-activation), injection site reactions, and sexual adverse events (spontaneous penile erections, sexual adverse reactions) per FDA label. Depression and suicidal ideation monitoring recommended.

Contraindications & Cautions

  • hard stop — Melanoma or history of melanoma
    Setmelanotide activates MC4R and has some MC1R activity. Melanocortin receptor activation stimulates melanocyte activity and could theoretically promote melanoma development, growth, or recurrence.
    Action: Do not use in patients with active melanoma or history of melanoma.
  • hard stop — Pregnancy
    Weight loss during pregnancy is not indicated and may cause fetal harm. Setmelanotide is contraindicated during pregnancy per IMCIVREE prescribing information.
    Action: Discontinue if pregnancy is detected. Do not initiate during pregnancy. Advise contraception.
  • hard stop — Breastfeeding
    Insufficient data on excretion in breast milk. Weight loss during breastfeeding may affect milk production.
    Action: Do not use while breastfeeding.
  • hard stop — Under 18 years of age
    FDA-approved only for specific genetic conditions under specialist care. Not for general pediatric use.
    Action: Do not provide outside specialist metabolic/genetic care.
  • monitor — Depression or suicidal ideation
    Suicidal ideation and depression have been reported in clinical trials of setmelanotide. Labeled warning per IMCIVREE prescribing information.
    Action: Monitor mood and mental health closely. Ensure mental health support is available. Discontinue and seek emergency care if suicidal ideation develops.
  • caution — Obesity without confirmed genetic etiology
    Setmelanotide (IMCIVREE) is FDA-approved ONLY for obesity due to specific genetic mutations (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome). It has not demonstrated efficacy in general obesity and should not be used off-label for this purpose.
    Action: Confirm genetic testing results before use. Not indicated for general or polygenic obesity.

Evidence

Research Summary

## Setmelanotide (Imcivree) — Research Summary ### Tier 1 (Strong Clinical Evidence) - **FDA approval (2020)**: Based on pivotal Phase 3 studies in POMC and PCSK1 deficiency obesity. Extended to LEPR deficiency (2022). - **Pivotal trials**: Open-label studies showed ≥10% weight loss in 80% of POMC deficiency patients and 45% of LEPR deficiency patients. Mean BMI reduction ~25%. - **Mechanism**: MC4R agonism is well-characterized. The melanocortin pathway in appetite regulation is supported by decades of research. - **Safety**: Well-characterized safety profile from clinical trials. Black box warning for depression/suicidal ideation. - **Genetic specificity**: Validated approach of treating specific genetic defects with targeted pharmacology. ### Tier 2 (Moderate Evidence) - **Additional genetic forms**: Ongoing studies evaluating setmelanotide in other genetic obesities (Bardet-Biedl syndrome, Alstrom syndrome, SH2B1 deficiency, MC4R heterozygous mutations). - **Bardet-Biedl syndrome**: Phase 3 trial showed significant weight loss, leading to expanded indication consideration. - **Long-term data**: Open-label extensions show sustained weight loss over 2+ years. ### Tier 3 (Emerging) - **Broader obesity application**: Whether MC4R agonism could benefit a wider population with partial melanocortin pathway dysfunction (not classic monogenic obesity) is being explored. - **Combination strategies**: Potential combination with GLP-1 agonists for additive appetite suppression in genetic obesity. ### Key Research Gaps - Long-term (5+ year) safety and efficacy data - Identification of additional genetic forms that respond to MC4R agonism - Whether partial MC4R agonism could benefit common obesity - Mood effects need better characterization

Build a personalized protocol with Setmelanotide →